secwatch.observer — SEC 8-K summary
======================================

Issuer:     Climb Bio, Inc. (CLYM)
CIK:        0001768446
Form:       8-K
Filed at:   2023-02-14T23:59:59+00:00
Accession:  0001193125-23-036503
Event type: other_material
Sentiment:  negative
Materiality: 0.90
Item codes: 2.02, 2.05, 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Eliem Therapeutics pauses ETX-155, cuts workforce 55%, CEO and CFO depart; cash $123.6M
--------------------------------------------------------------------------------

- Pauses development of ETX-155 (Phase 2-ready for MDD) to focus on preclinical Kv7.2/3 program (ETX-123).
- Workforce reduced by ~55% in first half 2023; estimated $17.1M restructuring charges ($7.3M cash).
- CEO Robert Azelby resigns; Andrew Levin appointed Executive Chairman; CFO Erin Lavelle and GC Jim Bucher also departing.
- Cash, cash equivalents and marketable securities $123.6M as of Dec 31, 2022; expected to fund operations into 2027.
- Plans to commence Phase 1 trial for ETX-123 in first half 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1768446/000119312523036503/0001193125-23-036503-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1768446/000119312523036503/d452795d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-036503

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer